ClinicalTrials.gg

Program

L03RD2

Its studies are mostly in Diabetes Mellitus, Type 2, led by Celltrion.

Furthest: phase 1, since Aug 28, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Celltrion20 open or runningphase 1since Aug 28, 2025Aug 28, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2025First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT07158346 · 49 enrolled · South Korea
  2. Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07533539 · 48 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07533539Diabetes Mellitus, Type 2 · South Korea1CompletedMay 28, 202648
NCT07158346Diabetes Mellitus, Type 2 · South Korea1CompletedOct 3, 202549

How it is read

Names in the registry

  • “L03RD2”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.